Drug profile

The FDA adverse-event record for Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture

78 FDA reports name Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#885 of 2,679
by report volume (all drugs)
78
adverse-event reports
6.4%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture ranks #884 of 2679 by total reports (78) and #723 of 1130 by death-coded share (6.4%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#884
This drug, reports of 2679
#723
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture has 78 reports now versus 78 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture changes

Signature read: 78 reports place Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture in the upper third of FDA AER volume (#885 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
78
Total Reports
5
Deaths Reported
6.4%
Death-coded share of reports

Active Ingredients

Bordetella Bronchiseptica, Modified Live, Avirulent Live CultureCanine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture

Administration Routes

NasalUnknownSubcutaneous

Species Affected

Dog 78

Most Affected Breeds

Chihuahua 6
Crossbred Canine/dog 6
Pit Bull 6
Shih Tzu 5
Retriever - Labrador 4
Dog (other) 4
Bulldog 3
Maltese 3
Shepherd Dog - Australian 3
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 3

Most Reported Reactions

Vomiting 29
Lethargy (see also Central nervous system depression in Neurological) 13
Lethargy (see also Central nervous system depression in 'Neurological') 10
Diarrhoea 9
Not eating 7
Seizure NOS 7
Elevated alanine aminotransferase (ALT) 5
Dry mucous membrane 5
Neutrophilia 5
Abnormal radiograph finding 4
Ataxia 4
Anorexia 4

Outcome Breakdown

Outcome Unknown
36 (46.2%)
Recovered/Normal
30 (38.5%)
Ongoing
7 (9.0%)
Died
3 (3.8%)
Euthanized
2 (2.6%)

Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture: high report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (6.4% here), distinct from the volume row.

Docp 6.4% Estriol Tablets 6.4% Neomycin Sulfate Equivalent To Neomycin Base + Nystatin + Thiostrepton 6.5% Oral Bordetella Vaccine 6.5%

What to do with this drug

  • Compare Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Bordetella Bronchiseptica, Modified Live, Avirulent Live Culture + Canine Parainfluenza Virus, Modified Live Virus, Avirulent Live Culture (#885 of 2,679 by report volume); death-coded 6.4%. PlainBreed drug row · report volume stamp 78 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →